ArticleCancer innovation2026
Low-Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer.
Article in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide clinical benefit in this setting, real-world evidence regarding their efficacy, safety, and optimal combination strategies remains limited. This study evaluated antiangiogenic therapy combined with chemotherapy in heavily pretreated MBC, with exploratory analyses across clinically relevant subgroups. Methods: This multicenter retrospective study enrolled 348 patients with heavily pretreated MBC who received antiangiogenic therapy plus chemotherapy or chemotherapy alone. A 1:1 propensity score-matched cohort of 174 pairs was generated for the primary comparative analysis. Chemotherapy backbones were categorized as microfilament-microtubule inhibitor (MMI)-based or non-MMI-based regimens. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR) and safety. Exploratory subgroup analyses were conducted according to antiangiogenic agent, chemotherapy backbone, prior lines of therapy, and dosing strategy. Results: In the propensity score-matched cohort, antiangiogenic therapy combined with chemotherapy was associated with significantly longer progression-free survival than chemotherapy alone (mPFS, 122 days [95% CI, 104-151] vs. 90 days [95% CI, 83-113]; HR, 0.62; 95% CI, 0.49-0.78; Conclusions: Antiangiogenic therapy combined with chemotherapy was associated with longer progression-free survival and a manageable safety profile in patients with heavily pretreated metastatic breast cancer. Exploratory analyses suggested that treatment outcomes may vary according to antiangiogenic agent, chemotherapy backbone, and prior treatment exposure. Dose-stratified analyses were descriptive and should not be interpreted as evidence of equivalence or non-inferiority between dose levels. Given the retrospective observational design, these findings should be considered hypothesis-generating and warrant prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.